Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 1/2010

Open Access 01-01-2010 | Commentary

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

Authors: P. C. Butler, A. V. Matveyenko, S. Dry, A. Bhushan, R. Elashoff

Published in: Diabetologia | Issue 1/2010

Login to get access

Excerpt

In the present edition of Diabetologia, Nachnani and colleagues report that rats treated with the glucagon-like-peptide-1 (GLP-1) mimetic, exendin-4, for 75 days developed low-grade pancreatitis [1]. The obvious question is whether low-grade pancreatitis is also present in humans treated with synthetic exendin-4 (exenatide) or other GLP-1-based therapies? The paper by Nachnani et al. is a timely addition to an area of growing interest and controversy in which, at present, there are more questions than answers. …
Literature
1.
2.
Cure P, Pileggi A, Alejandro R (2008) Exenatide and rare adverse events. N Engl J Med 358:1969–1970; discussion 1971-1962CrossRefPubMed
3.
Noel RA, Braun DK, Patterson RE, Bloomgren GL (2009) Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 32:834–838CrossRefPubMed
4.
Dore DD, Seeger JD, Arnold Chan K (2009) Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25:1019–1027CrossRefPubMed
5.
Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ (2009) Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 58:2148–2161CrossRefPubMed
6.
7.
Denker PS, Dimarco PE (2006) Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 29:471CrossRefPubMed
8.
Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A (2008) Exenatide and acute pancreatitis. J Assoc Physicians India 56:987–988PubMed
9.
10.
Buse JB, Rosenstock J, Sesti G et al (2009) Liraglutide once a day vs exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39–47CrossRefPubMed
11.
Matveyenko AV, Dry S, Cox HI et al (2009) Beneficial endocrine but adverse exocrine effects of Sitagliptin in the HIP rat model of type 2 diabetes, interactions with metformin. Diabetes 58:1604–1615CrossRefPubMed
12.
Herrera PL (2000) Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. Development 127:2317–2322PubMed
13.
Apelqvist A, Li H, Sommer L, Beatus P et al (1999) Notch signalling controls pancreatic cell differentiation. Nature 400:877–881CrossRefPubMed
14.
Papadopoulou S, Edlund H (2005) Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function. Diabetes 54:2844–2851CrossRefPubMed
15.
Wells JM, Esni F, Boivin GP et al (2007) Wnt/beta-catenin signaling is required for development of the exocrine pancreas. BMC Dev Biol 7:4CrossRefPubMed
16.
Rulifson IC, Karnik SK, Heiser PW et al (2007) Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci U S A 104:6247–6252CrossRefPubMed
17.
Heiser PW, Cano DA, Landsman L et al (2008) Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology 135:1288–1300CrossRefPubMed
18.
Gaisano HY, Gorelick FS (2009) New insights into the mechanisms of pancreatitis. Gastroenterology 136:2040–2044CrossRefPubMed
19.
Bhanot UK, Moller P (2009) Mechanisms of parenchymal injury and signaling pathways in ectatic ducts of chronic pancreatitis: implications for pancreatic carcinogenesis. Lab Invest 89:489–497CrossRefPubMed
20.
Whitcomb DC (2004) Mechanisms of disease: advances in understanding the mechanisms leading to chronic pancreatitis. Nat Clin Pract Gastroenterol Hepatol 1:46–52CrossRefPubMed
21.
Stevens T, Conwell DL, Zuccaro G (2004) Pathogenesis of chronic pancreatitis: an evidence-based review of past theories and recent developments. Am J Gastroenterol 99:2256–2270CrossRefPubMed
22.
Whitcomb DC, Gorry MC, Preston RA et al (1996) Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 14:141–145CrossRefPubMed
23.
Witt H, Luck W, Hennies HC et al (2000) Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 25:213–216CrossRefPubMed
24.
Sharer N, Schwarz M, Malone G et al (1998) Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 339:645–652CrossRefPubMed
25.
Taguchi M, Yamaguchi T, Otsuki M (2002) Induction of PDX-1-positive cells in the main duct during regeneration after acute necrotizing pancreatitis in rats. J Pathol 197:638–646CrossRefPubMed
26.
27.
Butler AE, Galasso R, Matveyenko A, Rizza RA, Dry S, Butler PC. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia doi:10.​1007/​s00125-009-1556-8
28.
Ehses JA, Perren A, Eppler E et al (2007) Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56:2356–2370CrossRefPubMed
29.
Stoffers DA, Kieffer TJ, Hussain MA et al (2000) Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49:741–748CrossRefPubMed
30.
Wettergren A, Wojdemann M, Holst JJ (1998) Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 275:G984–G992PubMed
31.
Landi S (2009) Genetic predisposition and environmental risk factors to pancreatic cancer: a review of the literature. Mutat Res 681:299–307CrossRefPubMed
32.
Jura N, Archer H, Bar-Sagi D (2005) Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Res 15:72–77CrossRefPubMed
33.
Crous-Bou M, Porta M, Morales E et al (2009) Past medical conditions and K-ras mutations in pancreatic ductal adenocarcinoma: a hypothesis-generating study. Cancer Causes Control 20:591–599CrossRefPubMed
34.
35.
Rebours V, Boutron-Ruault MC, Schnee M et al (2009) The natural history of hereditary pancreatitis: a national series. Gut 58:97–103CrossRefPubMed
36.
Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777CrossRefPubMed
37.
Yang YX (2009) Do diabetes drugs modify the risk of pancreatic cancer? Gastroenterology 137:412–415CrossRefPubMed
38.
Metadata
Title
Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?
Authors
P. C. Butler
A. V. Matveyenko
S. Dry
A. Bhushan
R. Elashoff
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1591-5

Other articles of this Issue 1/2010

Diabetologia 1/2010 Go to the issue

Letter

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Reply to Nagel JM, Mansmann U, Wegscheider K et al. [letter] and Simon D [letter]

Article

Relationship between fractional pancreatic beta cell area and fasting plasma glucose concentration in monkeys

Short Communication

Telomere length predicts all-cause mortality in patients with type 1 diabetes

List of Referees

List of referees

Letter

Duration of diabetes, glucose control and cardiovascular risk

Article

Efficacy of leptin therapy in the different forms of human lipodystrophy
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits